ArticleArchives of dermatological research2025
Therapeutic potential of phloridzin carbomer gel for skin inflammatory healing in atopic dermatitis.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Continuous treatment strategies improve psychological status and quality of life in patients with atopic dermatitis.World journal of psychiatry · 2025Article
- Phloridzin Mitigates Gorham-Stout Disease by Dual Inhibition of Osteoclastogenesis Related to the CaACS omega · 2025Article
- Exploring the Therapeutic Value of Some Vegetative Parts ofMolecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Phloridzin (PL), a natural compound derived from apples, exhibits diverse pharmacological properties including anti-inflammatory, anti-tumor, antioxidant, and anti-aging effects. The present study aimed to evaluate the impact of Phloridzin Carbomer Gel (PL-CG) on skin inflammatory healing in a mouse model of atopic dermatitis (AD). In vitro experiments initially determined the non-toxic concentration range of PL in cells, established a cellular inflammation model by stimulating cells with histamine to ascertain the optimal therapeutic concentration of PL, and subsequently detected decreased mRNA expression levels of relevant inflammatory cytokines, interleukins, through RT-qPCR experiments following PL treatment. For in vivo experiments, an AD mouse model was constructed. Histopathological analysis, along with assessments of epidermal thickness, reduction in scratch counts on the back of mice, and healing rates of inflammatory areas, indicated that PL-CG facilitates epidermal tissue regeneration and wound repair, thereby accelerating skin inflammatory healing. Additionally, PL-CG was subjected to microstructural observation using scanning electron microscopy (SEM), and experiments were conducted to determine its optimal pH value, stability, viscosity, and the influence of different concentrations of carbomer gel on drug release. The study demonstrated that PL-CG possesses anti-inflammatory and antipruritic properties, as well as the ability to promote skin inflammatory healing. Compared to traditional corticosteroids, PL-CG exhibits a higher safety profile and fewer side effects, suggesting broad prospects for its clinical application in the treatment of atopic dermatitis.
Indexed as
Identifiers
39915288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.